GlassScriptPhysician profile
Debra L Iselo
NPI 1437439353
$3,074.15
in general payments reported to CMS, 2019-2025
22 companies · $216 in 2025
The $216 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $731 · 2022: $1,223 · 2023: $542 · 2024: $361 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $939 · Education: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $938.96 |
| Education | $180.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $661.76 | 2021-2025 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $539.65 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $255.74 | 2021-2023 | |
| Daiichi Sankyo INC. | $151.22 | 2022-2023 | Enhertu |
| Lilly USA, LLC | $146.36 | 2022-2023 | Verzenio |
| Janssen Biotech, INC. | $141.80 | 2022 | |
| Genentech USA, INC. | $125.00 | 2022 | |
| Epizyme, INC. | $125.00 | 2021 | |
| Genmab U.S., INC. | $115.00 | 2023 | Tivdak |
| Pfizer INC. | $100.00 | 2022 | |
| Genzyme Corporation | $98.80 | 2025 | |
| Amgen INC. | $93.93 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $91.95 | 2024 | Rexulti |
| Acadia Pharmaceuticals INC | $88.00 | 2024 | Nuplazid |
| Argenx US, INC. | $87.60 | 2024 | Vyvgart Hytrulo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $79.50 | 2023 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $64.20 | 2022 | |
| Janssen Pharmaceuticals, INC | $29.56 | 2021 | |
| Misonix INC | $23.08 | 2021 | |
| Gt Medical Technologies, INC | $22.10 | 2022 | |
| Alexion Pharmaceuticals, INC. | $20.47 | 2022 | |
| Taiho Oncology, INC. | $13.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Iselo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.